DC Circ. Rejects Esai's Petition Over Seizure Med Delay

Law360, Chicago (October 25, 2013, 2:56 PM EDT) -- The D.C. Circuit on Tuesday shot down a bid from a U.S. unit of Japan’s Eisai Co. Ltd. to force the U.S. Drug Enforcement Administration to speed up the process for scheduling its epilepsy drug Fycompa as a controlled substance, saying the company had not shown the need for such drastic action.

In a brief order, the three-judge panel denied the drugmaker’s petition for a writ of mandamus. However, the decision came after the DEA agreed to take the initial step in the scheduling process by...
To view the full article, register now.